Inventiva S.A. SEC Filings

Inventiva S.A. announced an underwritten public offering of 38,961,038 ADSs at $3.85 per ADS, with a 30‑day option for underwriters to purchase up to 5,844,155 additional ADSs. The company expects net proceeds of approximately $140.1 million, or $161.2 million if the option is exercised in full, after underwriting commissions and estimated expenses.

The offering is being conducted under Inventiva’s Form F‑3 shelf that was deemed effective on November 3, 2025, and is expected to close on November 17, 2025, subject to customary closing conditions. Leerink Partners LLC and Piper Sandler & Co. are acting as underwriters. A legal opinion from Gide Loyrette Nouel A.A.R.P.I. has been filed in support of the issuance.

Inventiva S.A. (IVA) launched a primary offering of 38,961,038 American Depositary Shares at $3.85 per ADS under its shelf registration. The pricing implies a total offering size of $149,999,996, with underwriting commissions of $8,999,999 and estimated net proceeds of approximately $140.1 million. The company also granted underwriters a 30‑day option to purchase up to 5,844,155 additional ADSs at the public offering price, less commissions.

Inventiva plans to use roughly 80% of the proceeds to fund its NATiV3 Phase 3 MASH trial, prepare and initiate an outcomes trial, and support commercialization activities, and about 20% for working capital and general corporate purposes. Ordinary shares outstanding are expected to be 178,112,312 after the offering, or 183,956,467 if the option is fully exercised. The company notes immediate dilution of $3.12 per ADS to new investors.

Inventiva S.A. launched a preliminary prospectus supplement for a $125,000,000 primary offering of American Depositary Shares (ADSs), each representing one ordinary share. The ADSs trade on Nasdaq under “IVA,” and the ordinary shares trade on Euronext Paris as “IVA.”

The company states it will receive the proceeds and has granted underwriters a 30‑day option to purchase additional ADSs. Intended uses include funding the NATiV3 Phase 3 MASH program, preparation/initiation of an outcomes trial, commercialization activities, and general corporate purposes.

As context, cash and cash equivalents were €97.6 million and short‑term deposits were €24.7 million as of September 30, 2025. Ordinary shares outstanding were 139,151,274 as of June 30, 2025, and 146,272,305 as of November 10, 2025. The company discloses it expects to finance activities until the end of Q3 2026 and notes a material uncertainty that may cast significant doubt on its ability to continue as a going concern.

Inventiva S.A. announced its Ordinary and Extraordinary General Meeting, publishing the official notice on November 7, 2025. The meeting will take place on November 27, 2025 at 9 a.m. at Hôtel Villa M, 24-30 boulevard Pasteur, 75015 Paris, France.

The notice of meeting is furnished as Exhibit 99.1 to this Form 6-K and, as stated, is being furnished and not deemed filed under the Exchange Act.

Inventiva S.A. (IVA) announced proxy logistics for its upcoming shareholder meeting. The company began mailing its Proxy Card and Voting Instructions to beneficial owners of its American Depositary Shares in connection with its Ordinary and Extraordinary General Meeting to be held on November 27, 2025 at 9 a.m. at Hôtel Villa M, 24-30 boulevard Pasteur, 75015 Paris, France.

The materials are furnished on a Form 6-K with exhibits: 99.1 (Proxy Card) and 99.2 (Voting Instructions).

Inventiva S.A. announced its Ordinary and Extraordinary General Meeting. The meeting will be held on November 27, 2025 at 9 a.m. at Hôtel Villa M, 24-30 boulevard Pasteur, 75015 Paris, France.

The company published the notice of meeting and furnished it as Exhibit 99.1 to a Form 6-K. The Form 6-K states the information is being furnished, not filed, and that Inventiva files annual reports under cover of Form 20-F.